One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization - Gu, Maggie; Torres, Jonathan L.; Li, Yijia; Van Ry, Alex; Greenhouse, Jack; Wallace, Shannon; Chiang, Chi-I; Pessaint, Laurent; Jackson, Abigail M.; Porto, Maciel; Kar, Swagata; Li, Yuxing; et al. (Emerging microbes & infections, 2021)
Keywords: Animals; Antibodies, Neutralizing; Antibodies, Viral - blood; Antibody Formation; antibody-dependent enhancement (ADE); COVID-19 - prevention & control; COVID-19 vaccine; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Cricetinae; Humans; Immunization; Immunization Schedule; Immunogenicity, Vaccine; Mesocricetus; Mice; nanoparticle vaccine; Nanoparticles; Nanoparticles - chemistry; one-dose regimen; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Vaccination; vaccine safety; vaccine stability; variants; Viral Load; vaccine safety; SARS-CoV-2; nanoparticle vaccine; one-dose regimen; COVID-19 vaccine; antibody-dependent enhancement (ADE); variants; vaccine stability